null
ChEBI ID: 26763
| Member | Definition | Role |
|---|---|---|
| aldosterone 18-glucuronide | Aldosterone 18-glucuronide | |
| androsterone glucuronide | A steroid glucosiduronic acid having androsterone as the steroid component. | androsterone 3-glucosiduronic acid |
| dihydrotestosterone glucuronide | A steroid glucosiduronic acid that is 5alpha-dihydrotestosterone having a single beta-D-glucuronic acid residue attached at position 17. | 5alpha-dihydrotestosterone 17-O-(beta-D-glucuronide) |
| estradiol-17 beta-glucuronide | A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage. | 17beta-estradiol 17-glucosiduronic acid |
| estradiol-3-glucuronide | A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 3 via a glycosidic linkage. | 17beta-estradiol 3-glucosiduronic acid |
| estriol 3-glucuronide | A steroid glucosiduronic acid that is the 3-beta-D-glucuronide of estriol; a steroid hormone ligand recognised by the monoclonal antibody 4155. | estriol 3-O-(beta-D-glucuronide) |
| estriol-16 alpha-glucuronide | A steroid glucosiduronic acid that is estriol in which the phenolic hydrogen has been replaced by a beta-D-glucuronyl residue. | estriol 16-O-(beta-D-glucuronide) |
| estrone-3-glucuronide | The 3-beta-D-glucuronide of estrone. | estrone 3-O-(beta-D-glucuronide) |
| testosterone 17-glucosiduronate | A steroid glucosiduronic that is testosterone carrying a glucosiduronic acid residue at position 17. | testosterone 17-glucosiduronic acid |
| tetrahydroaldosterone 3 beta-glucosiduronic acid | Tetrahydroaldosterone-3-glucuronide |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 129 (31.16) | 18.7374 |
| 1990's | 103 (24.88) | 18.2507 |
| 2000's | 113 (27.29) | 29.6817 |
| 2010's | 57 (13.77) | 24.3611 |
| 2020's | 12 (2.90) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 28 (5.93%) | 5.53% |
| Reviews | 8 (1.69%) | 6.00% |
| Case Studies | 3 (0.64%) | 4.05% |
| Observational | 3 (0.64%) | 0.25% |
| Other | 430 (91.10%) | 84.16% |